Phase 1, multi-center, open-label, dose-escalation study to:~Evaluate the safety profile and MTD of RP-6306 with gemcitabine to establish the RP2D and schedule~Characterize the PK and pharmacodynamics of RP-6306 with gemcitabine~Assess preliminary anti-tumor activity associated with RP-6306 with gemcitabine
The primary purpose of this study is to assess the safety and tolerability of RP-6306 in combination gemcitabine, in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-6306 in combination with gemcitabine, identify a recommended phase 2 dose (RP2D) and preferred schedule, examine preliminary pharmacokinetics (PK) and assess anti-tumor activity.